Abstract

The long term objective of this work is to determine the efficacy of a novel oligonucleotide drug (AR177) against HIV in humans. The primary aim of this grant is to perform a Phase Ib, multiple-dose clinical trial of AR177.
Other aims are to perform a pharmacokinetic analysis of AR177 in the patient plasma from the Phase Ib clinical trial, and to determine the binding of AR177 to key blood constituents in vitro.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
2R44AI038788-02A1
Application #
2522815
Study Section
Special Emphasis Panel (ZRG5-ARRD (01))
Project Start
1995-09-01
Project End
1999-09-29
Budget Start
1997-09-30
Budget End
1998-09-29
Support Year
2
Fiscal Year
1997
Total Cost
Indirect Cost

  Institution

Name
Aronex Pharmaceuticals, Inc.
Department
Type
DUNS #
City
The Woodlands
State
TX
Country
United States
Zip Code
77380